Pulmonx Financials - Benzinga

Pulmonx Corp

LUNGNASDAQ

Trade with Public

Trade with Public

$1.91

-0.07-3.54%

al cierre: Sep 30, 5:00 PM EST

$1.91

N/A

After hour: 4:33 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Pulmonx Financials

Pulmonx (LUNG) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Pulmonx Affirms FY2026 Sales Guidance of $90.000M-$92.000M vs $90.832M Est

Pulmonx (NASDAQ:LUNG) affirms FY2026 sales outlook from $90.000 million-$92.000 million to $90.000 million-$92.000 million vs $90.832 million estimate.

Benzinga Newsdesk

PRO
Pulmonx Q2 EPS $(0.24) Beats $(0.28) Estimate, Sales $22.756M Beat $22.400M Estimate

Benzinga Newsdesk

PRO
Pulmonx Affirms FY2026 Sales Guidance of $90.000M-$92.000M vs $90.920M Est

Pulmonx (NASDAQ:LUNG) affirms FY2026 sales outlook from $90.000 million-$92.000 million to $90.000 million-$92.000 million vs $90.920 million estimate.

Benzinga Newsdesk

PRO
Pulmonx Q1 EPS $(0.33) Beats $(0.34) Estimate, Sales $20.586M Beat $20.432M Estimate

Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 8.33 percent increase over losses of $(0.36) per share from the same

Benzinga Newsdesk

Earnings Summary: Pulmonx Q4

Benzinga Insights

PRO
Pulmonx Sees FY2026 Sales $90.000M-$92.000M vs $94.227M Est

Pulmonx (NASDAQ:LUNG) sees FY2026 sales of $90.000 million-$92.000 million vs $94.227 million analyst estimate.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved